Ursodeoxycholic Acid and Atorvastatin in the Treatment of Nonalcoholic Steatohepatitis

Ursodeoxycholic Acid and Atorvastatin in the Treatment of Nonalcoholic Steatohepatitis

BACKGROUND/AIMS: Nonalcoholic steatohepatitis (NASH) is a serious disorder with the potential to gradually progress to cirrhosis. It is generally associated with obesity, diabetes and hyperlipidemia. Currently, there is no established therapy for NASH. The aim of the present study was to evaluate th...

Full description

Saved in:

Bibliographic Details
Main Authors:	Murat Kiyici, Macit Gulten, Selim Gurel, Selim Giray Nak, Enver Dolar, Gursel Savci, Saduman Balaban Adim, Omer Yerci, Faruk Memik
Format:	Article
Language:	English
Published:	Wiley 2003-01-01
Series:	Canadian Journal of Gastroenterology
Online Access:	http://dx.doi.org/10.1155/2003/857869
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The impact of the ursodeoxycholic acid as monotherapy and in the combination with the lactulose on the biochemical blood tests values of the nonalcoholic steatohepatitis patients
by: I. V. Mayev, et al.
Published: (2013-03-01)

Application of ursodeoxycholic acid at non-alcoholic and alcohol-induced steatohepatitis
by: Ye. A. Fedos’ina, et al.
Published: (2010-06-01)

Nonalcoholic Steatohepatitis in Nondiabetic Obese Patients
by: Idilio Zamin, et al.
Published: (2002-01-01)

Current Treatment Options for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
by: Melanie D Beaton
Published: (2012-01-01)

Treatment of Nonalcoholic Steatohepatitis in Adults: Present and Future
by: S. Gitto, et al.
Published: (2015-01-01)

Artificial Intelligence in Identifying Patients With Undiagnosed Nonalcoholic Steatohepatitis
by: Onur Baser, et al.
Published: (2024-09-01)

Nonalcoholic Steatohepatitis: More Than Just Being Fat
by: Eldon A Shaffer
Published: (2002-01-01)

LUBAC Formation Is Impaired in the Livers of Mice with MCD-Dependent Nonalcoholic Steatohepatitis
by: Yasuka Matsunaga, et al.
Published: (2015-01-01)

Steatohepatitis Is Not Associated with an Increased Risk for Fibrosis Progression in Nonalcoholic Fatty Liver Disease
by: Hannes Hagström, et al.
Published: (2018-01-01)

The Effect of Artichoke Leaf Extract on Alanine Aminotransferase and Aspartate Aminotransferase in the Patients with Nonalcoholic Steatohepatitis
by: Vajiheh Rangboo, et al.
Published: (2016-01-01)

Human Liver-Derived Stem Cells Improve Fibrosis and Inflammation Associated with Nonalcoholic Steatohepatitis
by: Stefania Bruno, et al.
Published: (2019-01-01)

Protective Role of Black Tea Extract against Nonalcoholic Steatohepatitis-Induced Skeletal Dysfunction
by: Subhra Karmakar, et al.
Published: (2011-01-01)

Hepatoprotective Effects of a Novel Trihoney against Nonalcoholic Fatty Liver Disease: A Comparative Study with Atorvastatin
by: Hamad Abdulsalam Hamad Alfarisi, et al.
Published: (2020-01-01)

Central Portalization Correlates with Fibrosis but Not with Risk Factors for Nonalcoholic Steatohepatitis in Steatotic Chronic Hepatitis C
by: Hwajeong Lee, et al.
Published: (2014-01-01)

Mouse Models of Nonalcoholic Steatohepatitis: Head-to-Head Comparison of Dietary Models and Impact on Inflammation and Animal Welfare
by: Andreas Kroh, et al.
Published: (2020-01-01)

Exploring and Verifying the Mechanism and Targets of Shenqi Pill in the Treatment of Nonalcoholic Steatohepatitis via Network Pharmacology and Experiments
by: Beihui He, et al.
Published: (2022-01-01)

CISD2-mediated mitochondrial dysfunction and iron redistribution contributes to ferroptosis in arsenic-induced nonalcoholic steatohepatitis
by: Jingyuan Zhang, et al.
Published: (2025-01-01)

Effect of Ursodeoxycholic Acid Alone and Ursodeoxycholic Acid Plus Domperidone on Radiolucent Gallstones and Gallbladder Contractility in Humans
by: Ilyas Tuncer, et al.
Published: (2012-01-01)

The AMPK–mTOR Pathway Is Inhibited by Chaihu Shugan Powder, Which Relieves Nonalcoholic Steatohepatitis by Suppressing Autophagic Ferroptosis
by: Zheng Liang, et al.
Published: (2024-01-01)

Differential Expression Profiles of mRNA and Noncoding RNA and Analysis of Competitive Endogenous RNA Regulatory Networks in Nonalcoholic Steatohepatitis
by: Mengjia Gao, et al.
Published: (2022-01-01)

MFG-E8 Knockout Aggravated Nonalcoholic Steatohepatitis by Promoting the Activation of TLR4/NF-κB Signaling in Mice
by: Jun Hu, et al.
Published: (2022-01-01)

Prevalence of Nonalcoholic Steatohepatitis and Associated Fibrosis Stages Among US Adults Using Imaging-Based vs Biomarker-Based Noninvasive Tests
by: Jesse Fishman, et al.
Published: (2024-02-01)

Ursodeoxycholic acid in complex treatment of metabolic syndrome
by: O. A. Tanchenko, et al.
Published: (2012-02-01)

Physicochemical Characteristics of Chitosan–Alginate Scaffold Containing Atorvastatin
by: Hananeh Hamedfar, et al.
Published: (2023-01-01)

Atorvastatin-Diltiazem Combination Induced Rhabdomyolysis Leading to Diagnosis of Hypothyroidism
by: N. D. B. Ehelepola, et al.
Published: (2017-01-01)

Atorvastatin Improves Inflammatory Response in Atherosclerosis by Upregulating the Expression of GARP
by: Xiaoqi Zhao, et al.
Published: (2015-01-01)

15-Lipoxygenase-1 Is Involved in the Effects of Atorvastatin on Endothelial Dysfunction
by: Peng Zhang, et al.
Published: (2016-01-01)

Flow Cytometric Analysis of T, B, and NK Cells Antigens in Patients with Mycosis Fungoides
by: Serkan Yazıcı, et al.
Published: (2015-01-01)

Comparative Effectiveness of Rosuvastatin Versus Atorvastatin in Acute Ischemic Stroke Treatment
by: Joon‐Tae Kim, et al.
Published: (2025-02-01)

Results of non-interventional observational study of ursodeoxycholic acid in primary biliary cirrhosis
by: Yelena N. Shirokova, et al.
Published: (2018-08-01)

Ursodeoxycholic acid for the treatment of hepatic sarcoid: A pre-post pilot study
by: Ethan Weinberg, et al.
Published: (2024-07-01)

Towards the Application of Atorvastatin to Intensify Proapoptotic Potential of Conventional Antileukemic Agents In Vitro
by: Jolanta D. Żołnierczyk, et al.
Published: (2015-01-01)

Ursodeoxycholic acid relieves clinical severity of COVID-19 in patients with chronic liver diseases
by: Tiantian Hu, et al.
Published: (2025-02-01)

A combination of ursodeoxycholic acid and Allium sativum prevents liver cirrhosis in cholestatic rats
by: Pratama Nurmalik Adhuri, et al.
Published: (2025-03-01)

The Role of Ursodeoxycholic Acid Administration During the COVID-19 Pandemic: A Questionnaire Survey
by: Cheng Zhou, et al.
Published: (2025-01-01)

Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis
by: D. V. Garbuzenko
Published: (2022-01-01)

Combination of autoimmune hepatitis to non-alcoholic steatohepatitis (Clinical case)
by: A. A. Driga, et al.
Published: (2010-11-01)

Investigation of non-alcoholic steatohepatitis in labidochromis caeruleus and xiphophorus hellerii
by: Mustafa Ünal Boyraz, et al.

Steatohepatitis-induced vascular niche alterations promote melanoma metastasis
by: Johannes Hoffmann, et al.
Published: (2025-01-01)

Development and Validation of RP-HPLC Method for Simultaneous Estimation of Ramipril, Aspirin and Atorvastatin in Pharmaceutical Preparations
by: Rajesh Sharma, et al.
Published: (2012-01-01)